Liafensine

Drug Profile

Liafensine

Alternative Names: BMS-820836; DB 104

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator AMRI
  • Developer Bristol-Myers Squibb; Denovo Biopharma
  • Class Antidepressants; Isoquinolines; Naphthalenes; Pyridazines; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Depressive disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 24 Apr 2017 Clinical trials in Depressive disorders in USA (PO)
  • 24 Apr 2017 Denovo Biopharma plans a biomarker driven clinical trial for Depressive disorders
  • 24 Apr 2017 Liafensine licensed to Denovo Biopharma worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top